TRAILBLAZER-ALZ (NCT03367403): A PHASE 2 DISEASE-MODIFICATION COMBINATION THERAPY TRIAL TARGETING MULTIPLE MECHANISMS OF ACTION ALONG THE AMYLOID PATHWAY